Kling Biotherapeutics
Team
Technology
Pipeline
News
Contact
Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies
Featured Article
Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies
Read More
24.07.25
Kling Bio Announces Collaboration with Sanofi for Accelerated Discovery of Neutralizing Antibodies
10.12.24
Kling Biotherapeutics Strengthens Leadership Team to Advance Pipeline Using its Proprietary Primary B-Cell Selection and Evolution Platform
31.10.24
Kling Biotherapeutics to Present Key Applications for its Primary B-Cell Immortalization, Screening and Antibody Optimization Platform Technologies at PEGS Europe
22.02.24
Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
05.12.23
Kling Bio Announces Appointment of Dr Stefano Gullà as Chief Scientific Officer
12.12.22
Kling Biotherapeutics Appoints Michael Koslowski, M.D. As Chief Executive Officer
29.09.22
Kling Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical trial of KBA1412 in Patients with Advanced Solid Tumors
Kling Biotherapeutics